On May 30th, 2025, the Journal of Translational Medicine published research co-authored by recent AFAR Grantee Cynthia Siebrand. The proof-of-concept explores using chimeric antigen receptors (CARs) for targeted Alzheimer’s therapies.
In a related Buck Institute for Research on Aging press release Siebrand shares, “This is an important proof-of-concept…It shows that we can harness existing Alzheimer’s antibody knowledge and convert it into a viable, adaptable cell therapy.”
Cynthia Siebrand is a current PhD candidate in the USC-Buck Biology of Aging Program and a 2024 Diana Jacobs Kalman/AFAR Scholarships for Research in the Biology of Aging recipient.
The senior author on the paper is Dr. Julie Andersen, who has served as member of several of AFAR's scientific review committees, including the National Scientific Advisory Council (NSAC).
Read “Chimeric antigen receptors discriminate between tau and distinct amyloid-beta species” here.
Read the related Buck Institute press release here.
